Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on November 6, 2025. The filing primarily addresses significant leadership transitions and references the announcement of financial results for the quarter ended September 30, 2025.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing financial results for the quarter ended September 30, 2025. However, the text of this 8-K does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for these figures.
Material Changes and Leadership Transitions
On November 6, 2025, the Company announced a restructuring of its leadership team effective January 1, 2026:
- Chief Financial Officer: Mario Ramos was appointed as the new CFO, effective January 1, 2026. He previously served as CFO of WellBe Senior Medical (2024-2025) and held senior roles at CVS Health and Edelman Financial Engines.
- Current CFO Transition: John Johnson will transition from CFO to Chief Strategy Officer effective January 1, 2026.
- Chief Operating Officer: Emily Rafferty will transition to a newly established role of EVP, Customer Success.
- Non-Clinical Operations: Katie DiPerna will assume the Chief Operations role for non-clinical services, reporting to President Dan McCarthy.
Compensation and Contractual Terms for New CFO
The Compensation Committee established the following terms for Mario Ramos:
- Base Salary: $550,000 annually.
- Variable Bonus: Maximum opportunity of $625,000 under the 2026 Bonus Plan.
- Sign-on Bonus: $100,000 payable on the Effective Date, subject to clawback provisions.
- Equity Grant: A special one-time RSU grant with a target value of $2,350,000, vesting over three years (34%, 33%, 33%). This grant offsets compensation forfeited from his prior employer.
- Severance:
- Non-Change in Control: 12 months of base salary, pro-rated bonus, and equity acceleration for the severance period.
- Change in Control: 1.5x base salary plus target bonus, pro-rated bonus, full equity vesting, and 18 months of COBRA subsidy.
Outlook, Risks, and Contingencies
The filing does not contain specific management commentary on future guidance, risks, or contingencies beyond the standard disclosure regarding the leadership changes. The financial results referenced in Item 2.02 are not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific revenue and profit figures for the quarter ended September 30, 2025, in the attached press release (Exhibit 99.1), as they are not detailed in this 8-K text.
- Confirm the exact start date of Mario Ramos's tenure (January 1, 2026) and the transition timeline for John Johnson.
- Review the full terms of the severance and change in control agreement to understand potential future liabilities.
- Assess the impact of the leadership restructuring on the Company's strategic direction, particularly the new role of EVP, Customer Success.